Celecoxib decreases growth and angiogenesis and promotes apoptosis in a tumor cell line resistant to chemotherapy

• Published in: Biological research 2014-06, Vol.47 (1), p.27-27, Article 27
• Main Authors: Rosas, Carlos, Sinning, Mariana, Ferreira, Arturo, Fuenzalida, Marcela, Lemus, David
• Format: Article
• Language: English
• Subjects: Angiogenesis; Angiogenesis Inhibitors - pharmacology; Animals; Anti-Inflammatory Agents, Non-Steroidal - pharmacology; Apoptosis - drug effects; BIOLOGY; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Celecoxib; Cell Line, Tumor; Cell Proliferation - drug effects; Chemotherapy; Chick Embryo; Chickens; Chorioallantoic Membrane; Dosage and administration; Drug Resistance, Neoplasm - drug effects; Drug Screening Assays, Antitumor; Drug therapy; Female; In Situ Nick-End Labeling; Lung Neoplasms - secondary; Mice; Neovascularization, Pathologic - drug therapy; Nonsteroidal anti-inflammatory agents; Physiological aspects; Pyrazoles - administration & dosage; Pyrazoles - pharmacology; Sulfonamides - administration & dosage; Sulfonamides - pharmacology; Tumor; Tumors; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - antagonists & inhibitors
• ISSN: 0717-6287; 0716-9760; 0717-6287
• DOI: 10.1186/0717-6287-47-27

During the last few years it has been shown in several laboratories that Celecoxib (Cx), a non-steroidal anti-inflammatory agent (NSAID) normally used for pain and arthritis, mediates antitumor and antiangiogenic effects. However, the effects of this drug on a tumor cell line resistant to chemotherapeutical drugs used in cancer have not been described. Cx reduces angiogenesis in the chick embryonic chorioallantoic membrane assay (CAM), inhibits the growth and microvascular density of the murine TA3-MTXR tumor, reduces microvascular density of tumor metastases, promotes apoptosis and reduces vascular endothelial growth factor (VEGF) production and cell proliferation in the tumor. The antiangiogenic and antitumor Cx effects correlate with its activity on other tumor cell lines, suggesting that Prostaglandins (PGs) and VEGF production are involved. These results open the possibility of using Celecoxib combined with other experimental therapies, ideally aiming to get synergic effects.